Sclerochoroidal calcification is an uncommon condition characterized by multiple placoid yellow-white subretinal lesions, typically located in the superotemporal mid-periphery of the fundus. While most cases are idiopathic in nature, at times they can be attributed to underlying systemic disorders involving abnormal calcium-phosphorous metabolism, most notably hyperparathyroidism or renal tubular hypokalemic metabolic alkalosis syndromes. We present a case of idiopathic sclerochoroidal calcification and provide recommendations for systemic evaluation.

**CASE REPORT**

A 68-year-old white man was referred for evaluation of an enlarging atypical lesion in his right eye, presumed to be an amelanotic choroidal melanoma. He had hyperlipidemia but denied having joint pains, skin or kidney diseases, Bartter or Gitelman syndrome, or ingesting calcium supplements. His diet consisted of moderate intake of yogurt and cheese. His serum calcium level at presentation was 9.9 mg/dL (normal 8.6-10.4), and potassium was 4.6 mmol/L (normal 3.5-5.5). Visual acuity was 20/25 in his right eye and 20/20 in the left eye. Slit-lamp examination of both eyes was unremarkable, and there was no evidence of Cogan scleral plaques in both eyes. Fundus examination of his left eye was unremarkable.

The fundus in his right eye displayed an amelanotic, yellow, lobular deep choroidal mass along the superotemporal vascular arcade, measuring 4 x 3 mm in basal diameter (Figure 1 A and B). Ultrasonography revealed a dome-shaped calcified lesion measuring 3.5 mm in thickness, with orbital shadowing on B-scan and high internal reflectivity on A-scan (Figure 1 C and D). Optical coherence tomography (OCT) showed an elevated choroidal lesion with no subretinal fluid (Figure 1 E). Amelanotic choroidal melanoma was in the differential diagnosis; however, absence of clinical symptoms, subretinal fluid, and the presence of an echodense, highly reflective lesion did not favor melanoma. The clinical features and the presence of ultrasonographic echodense calcium sug-

**Figure 1.** A 63-year-old white man with a yellow choroidal mass classified as sclerochoroidal calcification (A) in the right eye with slight hyperautofluorescence (B), dense calcification and shadowing on B scan (C) and A scan ultrasonography (D), and dramatic elevation with no subretinal fluid on optical coherence tomography (E).
gested sclerochoroidal calcification. The patient was observed without treatment, and metabolic evaluation was advised.

Systemic metabolic evaluation included calcium 10.2 mg/dL (normal 8.6-10.4), phosphate 4.0 mg/dL (normal 2.1-4.3), potassium 4.9 mmol/L (normal 3.5-5.5), magnesium 2.0 mg/dL (normal 1.5-2.5), parathyroid hormone 32 pg/mL (normal 10-65), and calcitonin <2 pg/mL (normal <10), all of which were within the normal ranges.

DISCUSSION

Sclerochoroidal calcification is a benign intraocular lesion with presumed dystrophic calcium deposition within the sclera and ultimate effacement of the choroid, manifesting as a yellow choroidal mass. It typically presents in older white patients (median age 70 years) and is characterized by multiple yellow-white lesions underlying the retina, superior to the superotemporal retinal vascular arcade of the mid-peripheral fundus. There appears to be some debate in the literature regarding tumor laterality, as some studies report visual field, and patients are typically asymptomatic. As there is little to no effect on visual acuity or devices or medications in this document.

In summary, we report a case of sclerochoroidal calcification with normal laboratory electrolytes, including serum calcium, phosphorus, potassium, and magnesium, and normal serum hormones, such as parathyroid hormone and calcitonin. We recommend screening tests for the aforementioned electrolytes and hormones in patients with this condition.

Supported in part by the Ocular Oncology Fund, Wills Eye Institute, Philadelphia, PA (CLS) and the Eye Tumor Research Foundation, Philadelphia, PA (CLS).

Rameet K. Hundle, BA, is currently a medical student at Loyola University, Chicago Stritch School of Medicine

Kiran Turaka, MD, is an Ocular Oncology Fellow at Wills Eye Institute, Thomas Jefferson University in Philadelphia.

Carol L. Shields, MD, is the Co-Director of the Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University. She is a Retina Today Editorial Board member. Dr. Shields can be reached at +1 215 928 3105; fax: +1 215 928 1140; or via e-mail at carol.shields@shieldsoncology.com.

The authors have no financial interest in the devices or medications in this document.


SHARE YOUR FEEDBACK

Would you like to comment on an author’s article? Do you have an article topic to suggest? We would like to hear from you. Please e-mail us at letters@bmctoday.com with any thoughts or questions you have regarding this publication.